

REMARKS

Claim Amendments

Claims 1, 3, 4 and 5 are amended in this Amendment B. In particular, claims 1, 3 and 4 are amended to more particularly define the compounds of the invention. No new matter has been added. Claim 5 has been amended to remove the term “pharmaceutical.” Upon entry of this amendment, claims 1-5 will be pending in the application.

Rejection under 35 U.S.C. §112

Claim 5 stands rejected under 35 U.S.C. § 112, first paragraph as containing subject matter which was not described in the specification in such a way to enable one skilled in the art to make and/or use the invention. This rejection is respectfully traversed in view of the amendments to claim 5. As described above, claim 5 has been amended to remove the term “pharmaceutical” to obviate the rejection. Amended claim 5 is now directed to “a composition useful for treating or preventing conditions mediated by the $\alpha_v\beta_3$ or $\alpha_v\beta_5$ integrin receptors in a mammal.” Reconsideration and withdrawal of the rejection is respectfully requested.

Rejection under 35 U.S.C. §102(b)

Claims 1-5 stand rejected under 35 U.S.C. §102(b) as being anticipated by Ruminski et al, WO 97/08145. The rejection is traversed.

Ruminski discloses a genus of compounds similar to the compound of claim 1 wherein X comprises a non-cyclic amino group. The instant claims, as amended, are distinguishable from Ruminski in that each of the claimed compounds contain an X substituent comprising a nitrogen-containing heterocycle. Accordingly, the amendments have obviated the rejection such that claims 1-5 define patentably over the cited reference. Reconsideration and withdrawal of the rejection is respectfully requested.


Conclusion

It is believed that all of the stated grounds of rejection have been properly traversed, accommodated, or rendered moot. Applicant therefore respectfully requests

that the Examiner reconsider and withdraw all presently outstanding rejections. It is believed that a full and complete response has been made to the outstanding Office Action, and as such, the present application is in condition for allowance. Thus, prompt and favorable consideration of this amendment is respectfully requested. If the Examiner believes that personal communication will expedite prosecution of this application, the Examiner is invited to telephone the undersigned at (314) 446-7683.

Applicants do not believe that any fee is owed by the timely submission of this amendment. However, the Commissioner is hereby authorized to charge any required fees to Deposit Account No. 08-0750. Further, if there is any other fee deficiency or overpayment of any fees in connection with this patent application, the Commissioner is hereby authorized to charge such deficiency or credit such overpayment to Deposit Account No. 08-0750.

Respectfully submitted,



James E. Davis, Reg. No. 47,516
Harness, Dickey & Pierce, P.L.C.
7700 Bonhomme, Suite 400
St. Louis, Missouri 63105
(314) 726-7500 (tel)
(314) 726-7501 (fax)